A group of three leading cancer centers has developed guidelines to determine which prostate cancer patients at risk for relapse should participate in a clinical trial and which compounds are appropriate in these studies.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.